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More than 1010 cells are generated every day in
the human intestine. Wnt proteins are key regu-
lators of proliferation and are known endoge-
nous mitogens for intestinal progenitor cells.
The positioning of cells within the stem cell
niche in the intestinal epithelium is controlled
by B subclass ephrins through their interaction
with EphB receptors. We report that EphB re-
ceptors, in addition to directing cell migration,
regulate proliferation in the intestine. EphB sig-
naling promotes cell-cycle reentry of progenitor
cells and accounts for approximately 50% of
the mitogenic activity in the adult mouse small
intestine and colon. These data establish EphB
receptors as key coordinators of migration and
proliferation in the intestinal stem cell niche.
INTRODUCTION
The proliferation of stem cells and their generation of prog-
eny need to be tightly regulated, as an overproduction
may result in tumor formation and an underproduction in
atrophy of the tissue. The proliferation of stem cells is or-
chestrated, in part, by neighboring cells, forming the stem
cell niche (Fuchs et al., 2004; Mikkers and Frise´n, 2005;
Watt and Hogan, 2000). The study of stem and progenitor
cells and their niches in model organisms have provided
important insights into their interplay through extracellular
signals (Spradling et al., 2001). The often more complex
structure of mammalian organs has made it more difficult
to elucidate how cells in a niche communicate to maintain
homeostasis.
The comparatively simple organization of the intestine
offers an attractive model in mammalian stem cell biology.
In the intestine, the epithelial lineage is contained within
a sheet of cells. Epithelial stem cells reside at or near
the bottom of crypts that are formed by the convolutionof the epithelial sheet. Members of the BMP (Haramis
et al., 2004; He et al., 2004) and hedgehog (Madison
et al., 2005; Ramalho-Santos et al., 2000; van den
Brink et al., 2004) families direct the positioning of the
crypts through an interplay between epithelial and subepi-
thelial cells.
Wnt proteins present at the bottom of the crypts induce
nuclear translocation of b-catenin, which is a pivotal fea-
ture of intestinal epithelial stem/progenitor cells (van de
Wetering et al., 2002). In concert with the Notch pathway,
b-catenin maintains intestinal stem cells and controls their
differentiation (Fre et al., 2005; Stanger et al., 2005; van de
Wetering et al., 2002; van Es et al., 2005). Experimental in-
hibition of the b-catenin pathway abolishes proliferation in
intestinal crypts, and mutations causing overactivation are
found in the vast majority of human intestinal cancers,
underscoring the central role of this pathway in controlling
cell proliferation and differentiation in the intestine (Reya
and Clevers, 2005).
As the progeny of the epithelial stem/progenitor cells
differentiate, the majority of cells migrate out of the crypt
and are shed into the lumen within one week. b-catenin
controls the positioning of cells within crypts by regulating
the expression of members of the ephrin and Eph families
(Batlle et al., 2002). Ephrin ligands and their Eph tyrosine
kinase receptors regulate cell migration in many contexts
(Holmberg and Frise´n, 2002; Palmer and Klein, 2003; Po-
liakov et al., 2004). Both ephrins and Eph receptors are
membrane bound proteins, restricting their interactions
to sites of direct cell-cell contacts. The ephrin-Eph recep-
tor interaction allows bidirectional communication, with
a signal being conveyed in both the receptor-expressing
(forward signaling) as well as in the ligand-expressing (re-
verse signaling) cell (Cowan and Henkemeyer, 2002;
Holmberg and Frise´n, 2002; Palmer and Klein, 2003; Pas-
quale, 2005).
Ephrins and Eph receptors negatively regulate the num-
ber of neurons generated from stem/progenitor cells in
the brain (Depaepe et al., 2005; Holmberg et al., 2005).
The transition from adenoma to colon carcinoma is asso-
ciated with loss of EphB receptor expression, and this isCell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc. 1151
an important step in the progression to invasive cancer
(Batlle et al., 2005; Guo et al., 2005; Jubb et al., 2005; Lugli
et al., 2005). This prompted us to analyze whether ephrins
and Eph receptors, in addition to their role in directing cell
migration, may participate in the control of proliferative
homeostasis in the intestinal stem cell niche.
We find by gain- and loss-of-function experiments that
B subclass ephrins and Eph receptors, independently of
their influence on cell positioning, promote proliferation
in the crypts of the small intestine and colon and account
for about 50% of the mitogenic activity. EphB2 and EphB3
kinase-dependent signaling promote cell-cycle reentry of
intestinal progenitor cells. These data establish that eph-
rins and Eph receptors are key coordinators of migration
and proliferation in the intestinal stem cell niche.
RESULTS
Reduced Proliferation in Colon Crypts in Mice
Lacking EphB2 and EphB3
Progenitor cells in the colon express EphB2 and EphB3,
whereas differentiating cells express ephrin-B1 and eph-
rin-B2 (Figures 1A and S1) (Batlle et al., 2002). As stem
cells cannot confidently be identified in the intestine we re-
fer to stem and progenitor cells collectively as progenitor
cells. We analyzed mice with null mutations in EphB2
and EphB3 (EphB2/; EphB3/) as well as mice that
lack EphB3 and have a kinase-inactive (ki) form of
EphB2 in which the intracellular domain is replaced by
b-galactosidase (EphB2ki/ki; EphB3/) (Henkemeyer
et al., 1996; Orioli et al., 1996). Whereas both forward
and reverse signaling is abolished in EphB2/; EphB3/
mice, reverse signaling through ephrin-Bs is maintained
in EphB2ki/ki; EphB3/ mice (Henkemeyer et al., 1996),
enabling the dissociation of the relative importance of
reverse and kinase-dependent signaling.
Progenitor cells in the colon reside at the bottom of ep-
ithelial invaginations known as the crypts of Lieberku¨hn
(Marshman et al., 2002; Sancho et al., 2004; Stappenbeck
et al., 1998). They give rise to absorptive enterocytes, the
main cell type of the epithelium, mucus-producing goblet
cells, and enteroendocrine cells. In both double mutant
combinations, we observed an approximately 50% de-
crease in the number of cells that were immunoreactive
for PCNA or Ki-67, markers of proliferating cells, or that in-
corporated BrdU in colon crypts (Figures 1B and 1D–1F).
There was no increase in the number of dying cells that
could explain the reduction in proliferating cells
(Figure 1C). These data establish EphB receptors as pos-
itive regulators of proliferation in colon crypts.
Redistribution of Proliferative Cells in the Crypts of
the Small Intestine inMice Lacking EphB2 andEphB3
Masks Altered Proliferation
In addition to the cell types produced in the colon, another
differentiated cell type, the Paneth cell, is generated in the
small intestine. Paneth cells are terminally differentiated
cells that have antimicrobial functions and are localized1152 Cell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc.at the bottom of the crypt (Ayabe et al., 2004). Progenitor
cells in the small intestine reside just above the Paneth cell
compartment (Marshman et al., 2002; Sancho et al., 2004;
Stappenbeck et al., 1998). Paneth cells express mainly
EphB3, which is required for their positioning, and the pro-
genitor cells above them in the crypt express mainly
EphB2, although there is an overlap in the expression do-
mains of EphB2 and EphB3 (Figures 2A and 2B) (Batlle
et al., 2002). Ephrin-B1 is expressed in a countergradient
in wild-type mice (Figures 2A and 2B), whereas ephrin-B1-
immunoreactive cells are scattered throughout the crypt in
EphB2; EphB3 mutant mice (Figure 2C) (Batlle et al.,
2002).
Analysis of the small intestine of adult EphB2; EphB3
mutant mice did not reveal any significant difference in
the total number of dividing cells, but a redistribution of
Figure 1. EphB2 and EphB3 Regulate Cell Proliferation in
Adult Mouse Colon
(A) EphB receptors, visualized by binding of ephrin-B2-Fc, are ex-
pressed in progenitor cells at the bottom of crypts in the colon, with
decreasing levels higher in the crypt. Ephrin-B1 is expressed in a coun-
tergradient with the lowest levels at the crypt bottom.
(B–F) The number of BrdU-incorporating, Ki-67- and PCNA-immuno-
reactive cells is reduced in EphB2; EphB3 mutant mice, but cell death
is unaltered. Data are represented as mean ± SEM. *** = p < 0.001.
Scale bars = 20 mm.
Figure 2. Redistribution of Proliferating
Cells in the Small Intestine of Mice Lack-
ing EphB2 and EphB3
(A and B) EphB3 is predominantly expressed
by Paneth cells and EphB2 by progenitor cells
in the small intestine, but their expression over-
laps. Ephrin-B1 immunoreactivity is localized
to differentiating cells higher in the crypt (A
and B), but these cells are distributed through-
out the crypt in the absence of EphB signaling
(C). EphB receptors and ephrin-B1 form coun-
tergradients and overlap in the middle of the
crypt (yellow in A and B). (A) and (B) show the
same crypt in adjacent sections.
(D–G) The total number of proliferative cells in
crypts of the adult small intestine of EphB2;
EphB3 mutant mice is not different from wild-
types (black bars in G), but their distribution
within the crypts is altered. Paneth cells are
mislocalized in the mutant mice, resulting in
a larger number of dividing cells at the very bot-
tom of the crypt (white bars in G). Proliferation
is reduced in the progenitor niche in the side
of the crypts (gray bars in G).
(H and I) The proportion of cells that are dividing
(proliferation index) in the different compart-
ments of the crypt in EphB2; EphB3 mutant
mice is compared to that in CR2-tox176 mice
(which lack Paneth cells; Stappenbeck et al.,
2003) to address the relative effect of EphB
signaling and cell redistribution on cell pro-
liferation. The result from mice of different ge-
notypes is compared to their respective wild-
type controls, which were set to 1. Data on
proliferation index in non-Paneth cells together
with data on the proportion of Paneth cells at
the crypt bottom from Stappenbeck et al.
(2003) were used to calculate the total prolifer-
ation index at the crypt bottom in CR-2tox176
mice.
(J) shows an illustration of how the loss of Pan-
eth cells (gray) at the bottom of crypts allows
proliferative cells (indicated by circular arrows)
to occupy this position and mask the reduced
proliferation in the normal stem/progenitor cell
compartment in the side of the crypt in the ab-
sence of EphB signaling. Data are represented
as mean ± SEM. ** = p < 0.01, *** = p < 0.001.
Scale bar = 10 mm.proliferating cells within the crypt was observed (Figures
2D–2G). The postmitotic Paneth cells are displaced from
the bottom of the crypts in the absence of EphB signaling
(Batlle et al., 2002), and this position becomes occupied
by progenitor cells, resulting in an increase in the number
of proliferating cells at the bottom of the crypt (white bars
in Figure 2G). This is reminiscent of the situation in mice
lacking Paneth cells, in which proliferation in the crypt is
increased (Garabedian et al., 1997; Stappenbeck et al.,
2003). However, analysis of cell proliferation in the side
of the crypt, where the majority of proliferating progenitor
cells normally are located, revealed a significant reductionin cell proliferation in this compartment in EphB2; EphB3
mutant mice relative to wild-type mice (gray bars in
Figure 2G). Thus, the mislocation of postmitotic Paneth
cells allows proliferation at the bottom of the crypt,
whereas proliferation in the normal progenitor niche is
reduced, thus resulting in similar total numbers of prolifer-
ating cells in the crypts of EphB2; EphB3 mutant and wild-
type mice.
This finding suggested that the loss of postmitotic Pan-
eth cells from the bottom of the crypt, allowing progenitor
cells to occupy this niche, might mask an effect of EphB
receptors on proliferation in the progenitor compartmentCell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc. 1153
Figure 3. Acute Inhibition of EphB Signaling In Vivo
Monomeric ephrin-B2 ectodomains (ephrin-B2), ephrin-B2-Fc, EphB2-Fc, Fc protein, or vehicle (PBS) was injected intravenously in adult mice.
(A) ELISA analysis of serum from injected animals demonstrates substantial levels of infused Fc proteins (detected with an antibody against human Fc)
3 days after the injection.
(B–E) Visualization of injected proteins with anti-human Fc antibodies in tissue sections of the small intestine fail to detect binding in Fc-injected an-
imals (B and D) but shows strong labeling restricted to crypts in animals receiving ephrin-B2-Fc (green in C and E). The binding of ephrin-B2-Fc closely
matches the pattern of EphB2 immunoreactivity (red) in the crypt (anti-Fc and anti-EphB2 are shown in the right half of the photo, and only anti-Fc in
the left half in D and E).
(F and G) Paneth cells (lyzozyme-immunoreactive, red) normally reside at the very bottom of the crypts and their position is unaltered in mice receiving
Fc as well as 1 day after an ephrin-B2-Fc injection.
(H and I) A few Paneth cells (indicated by arrowheads) are seen outside their normal compartment 3 days after injecting ephrin-B2-Fc (H), although not
as many as in EphB2; EphB3 mutant mice (I).
(J and K) The tyrosine phosphorylation of EphB2 in colon is reduced after ephrin-B2, ephrin-B2-Fc, or EphB2-Fc injections. Tyrosine phosphorylation
of the immunoprecipitated EphB2 receptor was visualized with phosphotyrosine-specific antibodies (upper panel in J) and normalized to EphB21154 Cell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc.
in the side of the crypt in small intestine. To address this
possibility, we compared proliferation in the different com-
partments of the crypt in EphB2; EphB3 mutant mice to
that in transgenic mice expressing the diphtheria toxin A
subunit under the Paneth cell-specific cryptidin-2 pro-
moter (CR2-tox176 mice) (Garabedian et al., 1997; Stap-
penbeck et al., 2003). CR2-tox176 mice lack Paneth cells
but are otherwise normal and thus allow the examination
of the effect of cell mislocation within the crypt on prolifer-
ation, without perturbing EphB signaling. In both EphB2;
EphB3 mutant mice and CR2-tox176 mice, there was an
increase in the number of proliferating cells in the crypt
bottom compared to wild-type mice due to the loss of
postmitotic Paneth cells from this compartment (Fig-
ure 2H). The relative increase in the number of proliferating
cells was larger in this compartment in CR2-tox176 mice
(approximately 5-fold) than in EphB2; EphB3 mutant
mice (approximately 3-fold), compared to their respective
wild-type controls. Most importantly, whereas there was
a significant reduction in proliferation in the normal pro-
genitor domain in the side of the crypt in the EphB2;
EphB3 mutant mice, there was no decrease in prolifera-
tion in this compartment in CR2-tox176 mice (Figure 2I).
The absence of Paneth cells from the crypts in CR2-
tox176 mice, but not in EphB2; EphB3 mutant mice, is ac-
companied by increased total proliferation (Garabedian
et al., 1997). Thus, the redistribution of proliferative cells
in the crypts of EphB2; EphB3 mutant mice, due to the
loss of postmitotic Paneth cells from the bottom of the
crypts, masks an effect on proliferation of EphB receptors
in the small intestine (illustrated in Figure 2J). This is in
contrast to the colon, which lacks Paneth cells, and where
there is an approximately 50% reduction in the number of
proliferative cells in the crypts in EphB2; EphB3 mutant
mice (Figure 1).
Analysis of either EphB2 or EphB3 single mutant mice
did not reveal significant alterations in cell proliferation in
any crypt compartment, indicating that these receptors
have, at least partly, redundant function in the regulation
of proliferation. Furthermore, cell death in small intestine
crypts was not significantly affected by abolished EphB
signaling (1.1 ± 0.2 in wild-type, 0.6 ± 0.1 in EphB2/;
EphB3/, and 0.7 ± 0.2 TUNEL+ cells/crypt and section
in EphB2ki/ki; EphB3/ mice, mean ± SEM, p > 0.05). Pro-
liferation was reduced by a similar magnitude in EphB2/;
EphB3/ and EphB2ki/ki; EphB3/ mice in both the colon
and in the side compartment in small intestine crypts (Fig-
ures 1B and 2G), establishing that the effect on prolifera-
tion is mediated by kinase-dependent signaling.
Acute Inhibition of EphB Signaling in the Intestine
The analyses of mutant mice demonstrate a role for EphB2
and EphB3 in regulating proliferation in the intestine, but it
remains difficult to dissociate the effect on migration froman effect on proliferation, especially in the small intestine.
Moreover, it is not possible from the analyses of mutant
mice to exclude the possibility that EphB receptors may
regulate an earlier developmental step and that the intes-
tinal progenitor cells at later time points are intrinsically dif-
ferent and less proliferative. We therefore sought to
acutely modulate EphB signaling in wild-type mice to an-
alyze the role of EphB signaling on progenitor proliferation
independent of cell positioning.
Ephrins have to be clustered in a cell membrane or arti-
ficially with, for example, antibodies to efficiently activate
Eph receptors (Davis et al., 1994; Stein et al., 1998). Un-
clustered soluble monomeric or dimeric ephrins bind
Eph receptors but are often weak agonists or antagonists
(Vearing and Lackmann, 2005). We administered unclus-
tered monomeric ephrin-B2 ectodomains (ephrin-B2),
ephrin-B2-Fc, antibody-clustered ephrin-B2-Fc, EphB2-
Fc, control Fc protein, or vehicle (PBS) systemically by in-
travenous injection to modulate EphB signaling acutely
in vivo in wild-type mice. The serum concentrations of
injected proteins were sufficiently high to maintain sig-
nificant systemic levels for several days (Figure 3A). Visu-
alization of injected proteins in sections of the intestine
revealed prominent ephrin-B2-Fc binding specifically in
the crypts of the intestine but did not reveal any bound
protein in animals receiving the control Fc protein (Figures
3B–3E). Visualization of injected ephrin-B2-Fc and endog-
enous EphB2 showed a close overlap indicating that
ephrin-B2-Fc specifically binds to EphB receptors in the
intestine (Figure 3E). We were unable to detect antibody-
clustered ephrin-B2-Fc complexes in the intestine (data
not shown), suggesting that they may be too large to
exit the vasculature.
One day after the injection of recombinant proteins, the
distribution of EphB2-expressing progenitor cells was un-
affected and no Paneth cells were seen outside their nor-
mal domain at the bottom of the crypt (Figures 3F and 3G).
However, in animals analyzed 3 days after the injection,
a few displaced Paneth cells started to appear, phenoco-
pying the EphB2; EphB3 mutant mice, indicating that
EphB signaling was inhibited (Figures 3H and 3I).
We next asked whether EphB receptor phosphorylation
was affected by the injection of ephrin-B2, ephrin-B2-Fc,
or EphB2-Fc. We found significantly reduced tyrosine
phosphorylation of EphB2 in the colon of ephrin-B2,
ephrin-B2-Fc, and EphB-Fc injected mice compared to
control Fc or vehicle-injected mice (Figures 3J and 3K),
establishing these reagents as antagonists of EphB sig-
naling in this context.
Acute Inhibition of EphB Signaling Reduces
Proliferation in the Small Intestine and Colon
Analysis of cell proliferation revealed that reduction in
EphB2 phosphorylation (Figure 3) was accompanied byprotein levels (lower panel in J). The tyrosine phosphorylation of EphB2 relative to PBS-injected animals is shown in (K). Cell nuclei are visualized with
DAPI, which appears blue. Data are represented as mean ± SEM. ** = p < 0.01 relative to PBS, Student’s t test.
Scale bar in (C) is 50 mm, 25 mm in (D), and 40 mm in (F).Cell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc. 1155
Figure 4. Inhibition of EphB Signaling Reduces Progenitor Proliferation
(A–E) Reduced proliferation in the small intestine 24 hr after injection of monomeric ephrin-B2 ectodomains (ephrin-B2), ephrin-B2-Fc, or EphB2-Fc.
(E) Quantification of BrdU-positive cells in the small intestine 24 hr after injection. Black bars represent the entire crypt, white bars represent the Pan-
eth cell compartment at the crypt bottom, and gray bars represent the side compartment of the crypts.
(F) The length of villi in the small intestine, relative to the respective control (which was set to 1), is reduced 3 days after an injection of ephrin-B2-Fc, but
not in EphB2; EphB3 mutant mice.
(G) The injection of ephrin-B2, ephrin-B2-Fc, or EphB2-Fc significantly reduces the number of proliferating cells in colon crypts 1 day later. Data are
represented as mean ± SEM. * = p < 0.05, ** = p < 0.005, *** = p < 0.001 relative to Fc, Student’s t test. The scale bar is 50 mm.a significant decrease in the total number of proliferating
cells in crypts of the small intestine as soon as 1 day after
the injection of ephrin-B2, ephrin-B2-Fc, or EphB2-Fc
compared to the control Fc protein (Figures 4A–4E). Quan-
tification of cell proliferation in the different compartments
of the crypt revealed that proliferation was unaffected or
mildly reduced in the Paneth cell compartment at the bot-
tom of the crypt but reduced to 45%–64% of that seen in
control Fc-injected animals in the progenitor domain in the
side of the crypt 1 day after the injection of ephrin-B2,
ephrin-B2-Fc, or EphB2-Fc (all p < 0.0005, Figure 4E). The
reduced proliferation upon acute inhibition of EphB sig-
naling was accompanied by a reduction in the length of
the villi in the small intestine after 3 days (Figure 4F). This
was in contrast to what was observed in EphB2; EphB3
mutant mice, where total proliferation (Figure 2) and villi
length were similar to that seen in wild-type mice (Fig-
ure 4F). A reduction in the number of BrdU-incorporating
cells to 48%–54% of that in Fc-injected animals was also
seen in the colon after injection of ephrin-B2, ephrin-B2-
Fc, or EphB2-Fc (all p < 0.001, Figure 4G), mimicking the
effect of EphB2 and EphB3 deletion (Figure 1). Apoptotic
cell death in crypts was not significantly affected by the
inhibition of EphB signaling (0.53 ± 0.03 and 0.42 ± 0.08
TUNEL+ cells/crypt and section in ephrin-B2-Fc and1156 Cell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc.Fc-injected animals, respectively, mean ± SEM, p >
0.05). Since cell positioning was unaffected 1 day after
the ephrin-B2-Fc or EphB2-Fc injections, and only mildly
affected after 3 days, this experiment dissociates the
role of EphB signaling on cell migration and proliferation.
The strong reduction in proliferation establishes a major
role for EphB receptors in regulating intestinal progenitor
proliferation, independent of their function in cell posi-
tioning.
Enhanced EphB Signaling Increases Progenitor
Proliferation
To further examine the potential role of EphB signaling on
intestinal progenitor cell proliferation, we devised two
gain-of-function strategies to examine the effect of in-
creased EphB signaling. In the first approach, we overex-
pressed the ligand ephrin-B2 in the intestinal epithelium
by electroporation in explant culture. The ephrin-B2 ex-
pression construct contained an IRES followed by GFP,
allowing us to visualize ephrin-B2-overexpressing cells
and to quantify the proliferation of adjacent cells (Figures
5A–5D). Overexpression of ephrin-B2 resulted in a statisti-
cally significant 44% increase in proliferation compared to
the GFP control construct (Figure 5E). Since these exper-
iments are performed in explant culture where the blood
circulation is disrupted, they argue against the effects of
EphB signaling on proliferation in the intestinal epithelium
as secondary to altered EphB function in the vasculature.
In a second gain-of-function approach, we generated
a point mutation in the mouse EphB2 gene to create a con-
stitutive, overactive kinase that does not require interac-
tions with ephrin ligands to transduce forward signals.
Based on the crystal structure of the autoinhibitory juxta-
membrane region of EphB2 and in vitro biochemical data
(Wybenga-Groot et al., 2001), we replaced the highly con-
served phenylalanine codon for residue 620 in EphB2 with
an aspartic acid codon (F620D) in the mouse germline
(Figure 5F). F620 is notable because it contributes to the
helical hydrophobic pocket of the unphosphorylated auto-
inhibitory segment that binds to and distorts the small
N-terminal lobe of the kinase domain, preventing it from
attaining an active conformation. The F620D substitution
is predicted to electrostatically disrupt the hydrophobic
contacts made by F620 with the surrounding negatively
charged groups in a manner mimicking phosphorylation
of Y610 (Wybenga-Groot et al., 2001). Thus, the catalytic
domain of the F620D mutant protein does become consti-
tutively active, as shown in vitro (Wybenga-Groot et al.,
2001). Since the F620D substitution does not interfere
with the two conserved juxtamembrane tyrosine residues
known to become phosphorylated and bind multiple SH2
domain-containing proteins, it is anticipated that the full
complement of forward signaling molecules should be
activated by this substitution.
Analysis of EphB2 tyrosine phosphorylation in the intes-
tine of mice heterozygous for the F620D mutation revealed
a statistically significant 67% increase compared to wild-
type littermates (Figures 5G and 5H). Analysis of prolifera-
tion in the small intestine revealed significantly more
BrdU-incorporating proliferative cells in mice heterozy-
gous (12%) or homozygous (19%) for the F620D mutation
compared to wild-type littermates (Figure 5I). The number
of BrdU-incorporating cells in the colon was 17% larger
in EphB2+/F620D (p > 0.05) and 30% larger in
EphB2F620D/F620D (p < 0.05) mice compared to wild-type
littermates (Figure 5J). Importantly, we could not detect
any signs of migration defects within the intestinal epithe-
lium of adult mice hetero- or homozygous for the F620D
mutation (Figure S2), dissociating the effect of EphB2 sig-
naling on proliferation and migration. Thus, EphB2 kinase
activity promotes proliferation in intestinal crypts in
a dose-dependent manner.
EphB Kinase-Dependent Signaling Conveys
the Mitogenic Signal
A similar reduction in intestinal progenitor cell proliferation
in mice lacking EphB2 and EphB3 signaling irrespective
of whether reverse signaling is abolished (EphB2/;
EphB3/) or maintained (EphB2ki/ki; EphB3/) estab-
lishes that kinase-dependent EphB signaling mediates
the effect on proliferation. We next asked whether the re-
duction in proliferation is in the EphB receptor-expressing
cells or whether it takes place in another cell type in theepithelium secondary to signaling in the receptor-ex-
pressing cells. We quantified the number of proliferating
cells with respect to their expression of ephrin-B1 or
EphB2 after acute inhibition of the ephrinB-EphB interac-
tion by an ephrin-B2-Fc injection. Analysis of BrdU incor-
poration in ephrin-B2-Fc and Fc control protein-injected
animals did not reveal a significant difference in the prolif-
eration of ligand-expressing cells (Figure 6A), whereas
there was a large decrease in the proliferation of recep-
tor-expressing cells accounting for all the reduction in pro-
liferation in ephrin-B2-Fc-injected animals (Figure 6B).
Thus, the proliferative effect of the ephrin-B/EphB path-
way in the intestine is mediated by kinase-dependent sig-
naling in EphB-expressing cells. This is in contrast to the
neural lineage, where EphA receptor signaling in stem
cells is inhibited by the expression of an endogenous
dominant-negative splice form of the receptor (Holmberg
et al., 2000), and ephrin-A reverse signaling negatively
regulates progenitor proliferation (Holmberg et al., 2005).
EphB Signaling Regulates Cell-Cycle Reentry
To gain insights into how EphB signaling regulates prolif-
eration in the intestine, we determined the cell-cycle
length and the cell-cycle reentry frequency in intestinal
progenitors. The length of the cell cycle is largely deter-
mined by the duration of the G1 phase, whereas the S
phase is subject to little variation. Analysis of the propor-
tion of cells in cycle (PCNA positive) that are in S phase
(BrdU incorporating within 1 hr) therefore gives a relative
indication of the cell-cycle length (Schmal, 1983). There
was no difference in the BrdU/PCNA labeling index be-
tween Fc- and ephrin-B2-Fc-injected animals (Figure 6C),
arguing against EphB signaling affecting cell-cycle length.
The frequency of cell-cycle reentry can be quantified by
first labeling cells in S phase by a BrdU pulse and then an-
alyzing what proportion of these cells are in cycle 24 hr
later (Chenn and Walsh, 2002). The lag time between
BrdU administration and analysis allows cells either to
exit (PCNA negative) or reenter the cell cycle (PCNA pos-
itive). There were 32% fewer cells reentering the cell cycle
in the crypts of ephrin-B2-Fc-injected mice compared to
Fc-injected mice in the small intestine (Figure 6D) and
35% fewer in the colon. Thus, EphB kinase signaling con-
trols proliferation of intestinal progenitor cells by promot-
ing cell-cycle reentry.
EphB Signaling Promotes Proliferation in Adenomas
The expression of EphB receptors is downregulated
during the progression of colorectal cancer and the loss
of EphB receptor expression correlates with a poor prog-
nosis (Batlle et al., 2005; Guo et al., 2005; Jubb et al.,
2005; Lugli et al., 2005). A direct role for EphB receptors
acting as tumor suppressors was demonstrated by the
development of invasive adenocarcinoma in a mouse
model of adenomatous polyposis (APCMin/+) when EphB
signaling was inhibited (Batlle et al., 2005). We tested
whether EphB signaling affects proliferation in adenomas
by injecting ephrin-B2-Fc in APCMin/+ mice. BlockingCell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc. 1157
Figure 5. Enhanced EphB Signaling Increases Proliferation
Misexpression of GFP (A) or ephrin-B2:IRES:GFP (B) by plasmid electroporation of intestinal explants. (B) ephrin-B2 immunoreactivity in an electro-
porated cell. A higher proportion of cells in contact with ephrin-B2-overexpressing cells incorporate BrdU compared to those adjacent to cells ex-
pressing GFP only (C–E). (F) Targeting of the F620D (codon 620: TTT/GAT) mutation to the mouse EphB2 gene. Coding sequences are represented
by filled boxes (exons) or filled arrows (positive or negative selectable markers, or DT-A). Filled arrowheads represent loxP sites. The origin of probes
used in Southern blotting analysis and relevant EcoRV (E), PsiI (Ps), and BclI (B) sites are indicated. Southern blotting analysis of three targeted ES cell
clones (1B6, 1E5, 1E8) subsequently used to create chimeric mice and establish germline transmission is shown below the targeting strategy. A non-
targeted clone (1B2) analyzed with the 30 probe is included to illustrate the increased mobility of the targeted allele. (G and H) Phosphorylation of1158 Cell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc.
Figure 6. EphB Signaling Promotes Pro-
genitor Cell-Cycle Reentry
(A and B) Analysis of BrdU incorporation in cells
immunoreactive (+) or not () for ephrin-B1 (A)
or EphB2 (B) 1 day after an injection of ephrin-
B2-Fc.
(C) The cell-cycle length is unaffected in ephrin-
B2-Fc-injected animals, but the frequency of
cells reentering the cell cycle is significantly
shortened (D). Injection of ephrin-B2-Fc in
APCmin/+ mice results in decreased prolifera-
tion 1 day later in small intestine crypts (E)
and in adenomas (F). Data are represented as
mean ± SEM. * = p < 0.05, ** = p < 0.01, *** =
p < 0.001, Student’s t test.EphB signaling reduced proliferation in small intestine
crypts in APCMin/+ mice to a similar degree as in wild-
type mice (Figure 6E) and reduced the number of BrdU-in-
corporating cells in adenomas by 41% 3 days after the in-
jection of ephrin-B2-Fc (Figure 6F). This suggests that the
tumor cells in the absence of EphB signaling may gain in-
vasiveness (Clevers and Batlle, 2006) at the expense of
proliferation.
EphB Signaling Controls the Size of the Proliferative
Domain but Not the Number of Stem or Progenitor
Cells
We next asked whether the altered proliferation in crypts
of EphB2; EphB3 mutant mice was due to a reduction in
the number of stem cells. Intestinal crypts each contain
an average of 1–2 stem cells, and the rest of the prolifera-
tive cells are progenitor cells (Marshman et al., 2002; San-
cho et al., 2004; Stappenbeck et al., 1998). Stem cells in
the intestine can be identified retrospectively by their
label-retaining capacity (Potten et al., 2002). If EphBs
regulate stem cell number, one would expect fewer
label-retaining cells in the absence of EphB signaling,but we did not find any difference between wild-type ani-
mals and EphB2; EphB3 mutants (Figure 7A). This also
demonstrates that EphB2 and EphB3 are not required
to keep stem cells from migrating out of the crypt, and
that other molecules mediate their anchoring in the niche,
at least over the time course and conditions of these
experiments.
Intestinal progenitor cells express musashi-1 (Kayahara
et al., 2003; Potten et al., 2003). We measured the length
of the domain of musashi-1-immunoreactive cells in the
crypt in ephrin-B2-Fc-, EphB2-Fc-, and Fc-injected ani-
mals to assess whether EphB signaling regulates the
progenitor cell pool size. The size of the progenitor cell
domains was independent of the EphB signaling status
(Figure 7B).
We next analyzed the length of the domain of prolifera-
tive cells in the crypt. Interestingly, the BrdU-incorporating
cells did not extend as far from the bottom of the crypt in
ephrin-B2-Fc or EphB2-Fc as in Fc-injected animals (Fig-
ures 4A–4C and 7C). Thus, EphB signaling regulates the
size of the proliferative compartment without an apparent
effect on the number of stem or progenitor cells.EphB2 is increased in anti-EphB2 immunoprecipitates from colon lysates of adult mice expressing the F620D substitution. This is accompanied by
increased BrdU incorporation in the small intestine (I) and colon (J). In (I), black bars represent the total crypt, white bars the crypt bottom, and gray
bars the crypt side. Abbreviations used in (F): P, promoter; PGK, phosphoglycerate kinase; Npt, neomycin phosphotransferase; pA, polyadenylation
signal; eIF4A1, eukaryotic initiation factor 4A1; DT-A, diphtheria toxin-A chain; TK, HSV thymidine kinase; N, novel exon. Data are represented as
mean ± SEM. * = p < 0.05, Student’s t test. The scale bar is 10 mm.Cell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc. 1159
Figure 7. Disruption of EphB Signaling
Does Not Alter the Progenitor or Stem
Cell Number but Reduces the Size of
the Proliferative Compartment
(A) Quantification of label-retaining cells did not
reveal a difference in stem cell numbers be-
tween EphB2; EphB3 mutant and wild-type
mice.
(B) The size of progenitor cell pool, as indicated
by musashi-1 (mshi) immunoreactive cells, is
unaltered in injected animals.
(C) shows the proportion of crypt in small intes-
tine that lacks BrdU-positive cells after injection
of ephrin-B2-Fc or EphB2-Fc.
(D) Wnt proteins are present at the bottom of
crypts and interact with receptors (WntR) in
epithelial cells, resulting in nuclear b-catenin
(indicated by filled nuclei) driving proliferation
(indicated by circular arrows). b-catenin drives
the expression of EphB receptors, which inter-
act with ephrin ligands higher in the crypt, ex-
tending the domain of proliferation. Postmitotic
Paneth cells (purple with granulae) occupy the
bottom of crypts in the small intestine. Data
are represented as mean ± SEM. * = p < 0.05,
Student’s t test.DISCUSSION
We report the identification of EphB receptors as major
regulators of proliferation in the intestinal stem cell niche.
Analysis of mutant mice and acute inhibition of EphB sig-
naling indicate that this pathway accounts for approxi-
mately 50% of the mitogenic activity in this lineage.
EphB kinase-dependent signaling in intestinal progenitor
cells promotes cell-cycle reentry and extends the prolifer-
ative domain in the crypts. The expression of ephrins and
Ephs in multiple adult stem cell systems (Figure S3) sug-
gests that they may control similar features in several or-
gans and may be attractive drug targets in regenerative
medicine.
Coupling of Migration and Proliferation in the
Intestinal Stem Cell Niche
The distorted migration in the small intestine caused by
the absence of EphB2 and EphB3 results in redistribution
of proliferative cells toward the source of Wnt proteins at
the bottom of the crypt, masking EphB receptors’ mito-
genic effect. The terminally differentiated Paneth cells
are lost from the crypt bottom and proliferative cells now
occupy this domain, whereas proliferation is reduced in
the side of the crypt, where dividing progenitor cells are
positioned.
The acute inhibition of EphB2 signaling by systemic de-
livery of ephrin-B2, ephrin-B2-Fc, or EphB2-Fc as well as
the generation of mice with constitutively active EphB2 re-
ceptors allowed us to discriminate between effects on cell
migration and proliferation. One day after the injection of
the inhibitory proteins, the distribution of EphB2-immuno-
reactive progenitor cells and Paneth cells is unaltered. In1160 Cell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc.this situation, there is, as in control mice, little proliferation
in the Paneth cell compartment at the bottom of the
crypts. However, proliferation in the progenitor domain
at the side of the crypt is then reduced to levels similar
to EphB2; EphB3 mutants. By avoiding the displacement
of Paneth cells and the mispositioning of cells along the
crypt-villus axis seen in EphB2; EphB3 mutant mice, we
were able to establish the role of EphB2 and EphB3 in pro-
liferation independently of their roles in controlling cell mi-
gration. Moreover, in mice expressing the EphB2 F620D
substitution, rendering the receptor constitutively active,
there is a dose-dependent increase in proliferation in the
progenitor domain in the absence of any migration defect.
The same challenge in dissociating migration and prolifer-
ation is not as apparent in the colon, where there are no
Paneth cells, and the reduction in proliferation was similar
in EphB2; EphB3 mutant mice and after acute inhibition of
EphB signaling.
Eph receptor signaling has not previously been reported
to promote cell proliferation in vivo. It is possible, however,
that Ephs may couple migration and proliferation in sev-
eral developmental contexts and that their mitogenic ef-
fects are masked by perturbed cell positioning in loss-
of-function models, as in the small intestine of the mutant
mice described in this study.
Ephrins and Eph Receptors in Intestinal
Homeostasis and Cancer
The expression of EphB receptors is frequently lost during
the progression of colorectal cancer, and this correlates
with a poor prognosis (Batlle et al., 2005; Guo et al.,
2005; Jubb et al., 2005; Lugli et al., 2005). The develop-
ment of invasive cancer in a mouse model of adenomatous
polyposis when EphB signaling was inhibited established
EphB signaling as inhibitory for cancer progression (Batlle
et al., 2005).
How can EphB receptors promote progenitor prolifera-
tion in the normal intestine and still act as tumor suppres-
sors in intestinal neoplasia? The mechanism by which
EphB signaling inhibits the development of invasive can-
cer is unclear, but Clevers and Batlle (2006) have postu-
lated that EphB signaling inhibits tumor cells from invading
surrounding repulsive ephrin-B-expressing areas. This is
supported by the fact that EphB2 expression is more com-
monly lost in metastases than in primary cancers (Guo
et al., 2005; Jubb et al., 2005). We found that inhibition
of EphB signaling reduced cell proliferation in adenomas
in APCmin/+ mice. This supports the hypothesis that the
tumor suppressor role of EphB receptors may be related
to restricting invasive growth, rather than inhibiting prolif-
eration. The loss of EphB expression allows invasive
growth but may come at the expense of a reduction in pro-
liferation. It is possible, however, that later stage cancer
cells have acquired mutations maximizing proliferation in-
dependently of EphB signaling. The larger size of tumors
in the absence of EphB signaling (Batlle et al., 2005) is
likely secondary to the invasive growth, with loss of spatial
restriction and possibly increased access to mitogens in
the tissue.
EphB Receptors Extend the Range of Wnt-Mediated
Proliferation
Wnt proteins are master regulators of cell proliferation in
the intestine. Their proliferative effects are, in part, medi-
ated by positive regulation of c-Myc expression and sup-
pression of p21 expression (van de Wetering et al., 2002).
EphB receptor expression in the intestine is under the con-
trol of Wnt proteins, and inhibition of this pathway results
in abolished EphB expression (Batlle et al., 2002; van de
Wetering et al., 2002). The present data demonstrate
that EphB receptor kinase signaling promotes intestinal
progenitor cell-cycle reentry and accounts for approxi-
mately 50% of the mitogenic activity in the intestine.
Thus, an important mechanism by which Wnt proteins
regulate proliferation in the intestine is by promoting
EphB expression.
Wnt proteins are poorly soluble palmitoylated proteins
(Willert et al., 2003), and their physical range of effect
may be rather limited. Only cells close to the bottom of
the crypts display nuclear b-catenin (Batlle et al., 2002).
EphB expression extends substantially higher up in the
crypt than the domain of cells with nuclear b-catenin
(Batlle et al., 2002). As cells move out of reach of the
Wnt proteins, they thus still maintain EphB receptor ex-
pression for some time, despite the fact that EphB expres-
sion is under the control of the Wnt pathway. This may be
related to translation of EphB mRNAs continuing for some
time after the transcription of EphB genes or that the EphB
proteins are stable in the cell membrane until the cells
encounter ligand higher in the crypt. Importantly, the ex-
pression of ephrin-Bs is negatively regulated by b-catenin(Batlle et al., 2002), which limits cells expressing EphB to
encounter ligand until they move out of the domain of
high Wnt protein concentration.
By controlling the expression of a class of stable mem-
brane bound signaling proteins, and negatively regulating
the expression of its cognate ligand, it appears that the ef-
fect of a localized Wnt protein morphogen gradient can be
extended to a larger domain beyond the region of high Wnt
protein concentration (Figure 7D). This is supported by the
shortening of the domain of proliferative cells toward the
bottom of the crypts after inhibition of EphB signaling.
The coupling of cell positioning and proliferation by the
ephrin-Eph pathway may thus serve to amplify and extend




Tissues from EphB2 and EphB3 mutant mice on CD1 genetic back-
ground (Henkemeyer et al., 1996; Orioli et al., 1996) were dissected
and coded by genotype in one laboratory (M.H.) and all analyses
were done blind to genotype in the other laboratory (J.F.). Adult male
C57/Bl6 mice were used for injection experiments.
Generation of Mice with Constitutively Active EphB2
A contig was assembled in pBeloBAC11 from previously described ge-
nomic mouse EphB2 l phage DNA clones 5.2 and 7.2 (Henkemeyer
et al., 1996) using homologous recombination in E. coli. EphB2 exon
11 was then targeted, again using homologous recombination in
E. coli, with a pL452-based minitargeting vector containing EphB2 ho-
mology arms (a wild-type 400 bp 50-arm and a codon 620-mutated
(TTT/GAT) 30-arm) to yield pBeloBAC11.EphB2.F620D. An EphB2
targeting vector was produced by homologous recombination-medi-
ated retrieval of an F620D-containing fragment from pBeloBAC11.
EphB2.F620D into pL254 (a modified form of pL2451 [Liu et al.,
2003] with a DT-A expression cassette and unique AscI site for linear-
ization). All sequences and details of DNA engineering are available
upon request. R1 ES cells were electroporated with AscI-linearized
pL254.EphB2.F620D, then subjected to selection and screened by
Southern blotting with the 50-probe. The floxed PPGK/EM7.npt.pA
cassette was deleted in the mouse germline by crossing to Krox20-
Cre recombinase-expressing males. Genotyping was performed using
a two-allele three-primer touchdown PCR using the oligonucleotides
neoF2 (50- TTGGCTACCCGTGATATTGCTGAA-30), F620DgF1 (50-GG
GGGACTCTTCACCGACTAA-30), and F620DgR1 (50-CAAGGGGAACA
GAGATCAGAAAAG-30). Products were diagnostic of wild-type (257
bp), F620D (635 bp), and F620D neo (389 bp) alleles.
Analysis of Proliferation and Cell Death
BrdU (100 mg/kg in 0.9% NaCl) was injected intraperitonealy 2 or 24 hr
prior to sacrifice. For visualization of label-retaining cells, BrdU was in-
jected once every 12 hr for 3 days, and the mice sacrificed 3 weeks
later (Potten et al., 2002). Data on proliferation index in non-Paneth
cells together with data on the proportion of Paneth cells at the crypt
bottom from Stappenbeck et al. (2003) was used to calculate the pro-
liferation index in germ-free CR-2tox176 mice. Apoptotic cells were
detected with the Apoptag Peroxidase In Situ Apoptosis Detection
Kit (Chemicon International).
Immunohistochemistry
Mice were perfused transcardially with 4% formaldehyde in PBS, the
isolated tissues cryoprotected in 20% sucrose in PBS overnight, and
sections were cut on a cryostat. Goat anti-EphB2 and anti-EphB3Cell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc. 1161
were used at 1:500 (R&D Systems), rat anti-ephrin-B1 at 1:2.5 (RPMI
1640, gift from H. Okano), rat anti-BrdU at 1:200 (BD Immunocytome-
try Systems), anti-PCNA at 1:400 (Oncogene), rabbit anti-lyzozyme at
1:250 (DakoCytomation), and rat anti-musashi-1 at 1:10,000 (Kaneko
et al., 2000). Sections used to visualize BrdU- and/or PCNA-immuno-
reactive nuclei were pretreated with 2M HCl and 0.5% Triton X-100
(Sigma) for 30 min at 37ºC. To detect infused Fc-chimeras, sections
were incubated with either AlexaFlour 488 conjugated goat anti-hu-
man or Cy3 donkey anti-human at 1:500. For all immunohistochemis-
try, control studies included exclusion of the primary antibody, which
resulted in the absence of immunoreactivity. In addition, the specificity
of antisera against EphB2 and EphB3 was confirmed by abolished la-
beling in sections from the respective null mice (Figure S1).
Delineation of Crypt Compartments
Crypts in the small intestine were divided into a Paneth compartment
and a side compartment for quantification. This was done based on
area rather than localization of Paneth cells since they are misposi-
tioned in the mutant mice. The area of the Paneth compartment was
determined in tissue sections in the microscope in five wild-type crypts
in which Paneth cells were visualized with antibodies against lyzo-
zyme. The average area was calculated from this measurement, and
the corresponding area at the bottom of all crypts in the small intestine
was defined as the Paneth compartment. The part of the crypt not har-
boring Paneth cells was defined as the side compartment. Together
the Paneth compartment and the side compartment compose the total
crypt.
Protein Injections
Recombinant mouse ephrin-B2, ephrin-B2-Fc, EphB2-Fc, or human
Fc (100 mg/mouse, R&D systems) in PBS were injected intravenously
via the tail vein, and serum concentrations were measured by ELISA.
Monomeric ephrin-B2 ectodomains were generated by cleaving
ephrin-B2-Fc with Factor Xa protease at the IEGR sequence between
Fc and the ephrin-B2 ectodomain. Fc fragments and uncleaved pro-
tein were removed with Protein A-sepharose, and the purity of the cor-
rect fragment was verified by SDS-PAGE.
Immunoprecipitation and Immunoblotting
Mice were sacrificed 24 hr after injection with Fc proteins, the ascend-
ing colon was dissected out, and the tissue solubilized in 2 ml of lysis
buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 1% Triton X-100, 20 mM
Hepes, 10% glycerol, 0.1% BSA, 20 mM sodium fluoride, 2 mM PMSF,
100 mM sodium orthovanadate, 100 U/ml Trasylol [aprotinin], and 0.05
mM Leupeptin) and centrifuged at 13,000 g for 10 min. For immunopre-
cipitation of EphB2, lysates were incubated with 2 mg/ml of goat anti-
mouse EphB2 antibody (R&D Systems) and 40 ml protein A Sepharose
for 5 hr. The beads were washed three times in 1% Triton X-100 in PBS
and the protein samples were separated by 4%–12% NuPAGE fol-
lowed by Western blot analysis with an anti-phosphotyrosine antibody
(4G10, Upstate), an anti-phospho-Eph antibody (Dalva et al., 2000), or
anti-EphB2 antibody (R&D Systems).
Electroporation and Explant Culture
Small intestine from E16 embryos was dissected out and expression
plasmids for ephrin-B2 and GFP or GFP only (10 mg/ml) were injected
into the lumen of 0.5 cm long segments. The tissue was submerged in
PBS and subjected to five pulses (80 V and 50 ms) utilizing an ECM830
electroporator from BTX. After electroporation, the tissue was put in
catenary culture as described (Hearn et al., 1999) and grown in
DMEM:F12 with 10% FBS and 1% penicillin/streptomycin for 15 hr.
BrdU (40 mg/ml) was added to the medium 1 hour before fixation in
4% formaldehyde.1162 Cell 125, 1151–1163, June 16, 2006 ª2006 Elsevier Inc.Supplemental Data
Supplemental Data includes three figures and references and can be
found with this article online at http://www.cell.com/cgi/content/full/
125/6/1151/DC1/.
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